Canaccord lowered the firm’s price target on Evolent Health (EVH) to $9 from $16 and keeps a Buy rating on the shares. The firm lowered its target by removing the premium valuation it had previously as the uncertainty on how ACA open enrollment will turn out as the shutdown ends without action on extending enhanced subsidies has put shares in limbo until more clarity emerges once open enrollment is completed. This and uncertainty on MA and Medicaid membership changes are holding the stock hostage near-term and overshadowing longer-term reasons to invest in Evolent.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVH:
- Evolent Health: Strong Growth Prospects and Strategic Market Positioning Justify Buy Rating
- Evolent Health: Positioned for Growth with Strong Fundamentals and Valuation Upside
- Evolent Health upgraded to Overweight at Stephens with sentiment near bottom
- Evolent Health upgraded to Overweight from Equal Weight at Stephens
- BMO Capital’s Optimistic Buy Rating for Evolent Health Driven by Strategic Stabilization and Growth Initiatives